Access cutting-edge anca-associated vasculitis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access anca-associated vasculitis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related anca-associated vasculitis treatment provided free
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this anca-associated vasculitis clinical trial in New York, NY
If you're searching for anca-associated vasculitis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced anca-associated vasculitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.